Groupama Asset Managment Cuts Position in BioNTech SE Sponsored ADR $BNTX

Groupama Asset Managment decreased its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 13.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 193,402 shares of the company’s stock after selling 29,823 shares during the period. Groupama Asset Managment’s holdings in BioNTech were worth $19,073,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BNTX. Krensavage Asset Management LLC increased its holdings in BioNTech by 8.2% in the third quarter. Krensavage Asset Management LLC now owns 79,366 shares of the company’s stock valued at $7,827,000 after buying an additional 5,984 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of BioNTech by 10.8% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 9,552 shares of the company’s stock worth $935,000 after acquiring an additional 933 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of BioNTech during the 3rd quarter worth approximately $1,459,000. Alyeska Investment Group L.P. acquired a new stake in shares of BioNTech in the 3rd quarter worth approximately $5,687,000. Finally, Scientech Research LLC purchased a new position in BioNTech in the 3rd quarter valued at approximately $517,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Truist Financial set a $155.00 price objective on BioNTech in a report on Tuesday, March 10th. Morgan Stanley lowered their target price on BioNTech from $134.00 to $125.00 and set an “overweight” rating on the stock in a report on Tuesday, March 10th. Jefferies Financial Group cut their price target on BioNTech from $151.00 to $138.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $140.00 price objective on shares of BioNTech in a research note on Thursday, December 11th. Thirteen investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.73.

BioNTech Price Performance

BNTX stock opened at $90.00 on Thursday. The stock’s 50 day moving average price is $106.04 and its 200 day moving average price is $102.34. The firm has a market cap of $21.60 billion, a P/E ratio of -17.18 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.